OncoLoop: A Network-Based Precision Cancer Medicine Framework
Cancer Discovery · 06.02.2023 · 13 (2) · 386-409
DOI: 10.1158/2159-8290.cd-22-0342 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Discovery, online erschienen am 14.11.2022. Verfasst von Alessandro Vasciaveo und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Biology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Prioritizing treatments for individual patients with cancer remains challenging, and performing coclinical studies using patient-derived models in real time is often unfeasible. To circumvent these challenges, we introduce OncoLoop, a precision medicine framework that predicts drug sensitivity in human tumors and their preexisting high-fidelity (cognate) model(s) by leveraging drug perturbation profiles. As a proof of concept, we applied OncoLoop to prostate cancer using genetically engineered mouse models (GEMM) that recapitulate a broad spectrum of disease states, including castration-resistant, metastatic, and neuroendocrine prostate cancer. Interrogation of human prostate cancer cohorts by Master Regulator (MR) conservation analysis revealed that most patients with advanced prostate cancer were represented by at least one cognate GEMM-derived tumor (GEMM-DT). Drugs predicted to invert MR activity in patients and their cognate GEMM-DTs were successfully validated in allograft, syngeneic, and patient-derived xenograft (PDX) models of tumors and metastasis. Furthermore, OncoLoop-predicted drugs enhanced the efficacy of clinically relevant drugs, namely, the PD-1 inhibitor nivolumab and the AR inhibitor enzalutamide. Significance: OncoLoop is a transcriptomic-based experimental and computational framework that can support rapid-turnaround coclinical studies to identify and validate drugs for individual patients, which can then be readily adapted to clinical practice. This framework should be applicable in many cancer contexts for which appropriate models and drug perturbation data are available. This article is highlighted in the In This Issue feature, p. 247
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Systems Biology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York.
- Department of Molecular Pharmacology and Therapeutics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York.
- Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York.
- Department of Genetics and Development, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York.
- Department of Urology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York.
- Department for Biomedical Research, University of Bern, Bern, Switzerland.
ORCID-Profile: Alessandro Vasciaveo, Juan Martín Arriaga, Francisca Nunes de Almeida, Min Zou, Florencia Picech, Maho Shibata, Antonio Rodriguez-Calero, Simone de Brot, Antonina Mitrofanova, Chee Wai Chua, Charles Karan, Ronald Realubit, Sergey Pampou, Jaime Y Kim, Stephanie N Afari, Timur Mukhammadov, Luca Zanella, Eva Corey, Mariano J Alvarez, Mark A Rubin, Michael M Shen, Andrea Califano, Cory Abate-Shen
Förderung
- NCI NIH HHS
- NIH HHS
- NCATS NIH HHS
- National Cancer Institute
Zitieren
APA
Vasciaveo, A., Arriaga, J. M., de Almeida, F. N., Zou, M., Douglass, E. F., Picech, F., Shibata, M., Rodriguez-Calero, A., de Brot, S., Mitrofanova, A., Chua, C. W., Karan, C., Realubit, R., Pampou, S., Kim, J. Y., Afari, S. N., Mukhammadov, T., Zanella, L., Corey, E., …, & Abate-Shen, C. (2023). OncoLoop: A Network-Based Precision Cancer Medicine Framework. Cancer Discovery, 13(2), 386-409. https://doi.org/10.1158/2159-8290.cd-22-0342
Vancouver
Vasciaveo A, Arriaga JM, de Almeida FN, Zou M, Douglass EF, Picech F, et al. OncoLoop: A Network-Based Precision Cancer Medicine Framework. Cancer Discovery. 2023;13(2):386-409. doi:10.1158/2159-8290.cd-22-0342
BibTeX
@article{Vasciaveo2023,
author = {Vasciaveo, Alessandro and Arriaga, Juan Martín and de Almeida, Francisca Nunes and Zou, Min and Douglass, Eugene F and Picech, Florencia and Shibata, Maho and Rodriguez-Calero, Antonio and de Brot, Simone and Mitrofanova, Antonina and Chua, Chee Wai and Karan, Charles and Realubit, Ronald and Pampou, Sergey and Kim, Jaime Y and Afari, Stephanie N and Mukhammadov, Timur and Zanella, Luca and Corey, Eva and Alvarez, Mariano J and Rubin, Mark A and Shen, Michael M and Califano, Andrea and Abate-Shen, Cory},
title = {OncoLoop: A Network-Based Precision Cancer Medicine Framework},
journal = {Cancer Discovery},
year = {2023},
volume = {13},
number = {2},
pages = {386--409},
doi = {10.1158/2159-8290.cd-22-0342}
}
EUVIMED